Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding Economic Decision-Making in Digital Therapeutics Development: Qualitative Approach.

Journal of medical Internet research·2025
Same author

A group concept mapping study of stakeholder perspectives on digital therapeutics economic value drivers.

NPJ digital medicine·2025
Same author

Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review.

Journal of medical Internet research·2023
Same author

Costing bias in economic evaluations.

Journal of medical economics·2015
Same author

Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.

Drug discovery today·2008
Same author

Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine.

Current medicinal chemistry·2008
Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Needed: system dynamics for the drug discovery process.

Suzanne Sirois1, L Martin Cloutier

  • 1Department of Chemistry, University of Quebec at Montreal, C.P. 8888 Succ. Centre-Ville, Montreal, QC, Canada H3C 3P8. suzanne.sirois@gmail.com

Drug Discovery Today
|August 5, 2008
PubMed
Summary
This summary is machine-generated.

This study introduces a system dynamics model to improve decision-making in the drug discovery process (DDP). It aims to enhance early-stage technology integration for better R&D outcomes and reduced delays.

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Related Experiment Videos

Last Updated: Jul 3, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Area of Science:

  • Pharmaceutical Sciences
  • Systems Engineering
  • Management Science

Background:

  • The drug discovery process (DDP) is complex with interconnected feedback loops influencing early-stage decisions and later-stage performance.
  • Current decision-making in DDP often lacks a systemic perspective, leading to imprecise mental models and limited process improvements.
  • There is a need for integrated approaches to address challenges in early DDP, such as attrition rates and lead identification.

Purpose of the Study:

  • To develop a system dynamics structure for characterizing the relationship between technology and management decisions in the DDP.
  • To provide decision-makers with a systemic perspective to improve their mental models and drive genuine process improvements.
  • To explore the integration of technology and knowledge-based approaches for early-phase DDP optimization.

Main Methods:

  • System dynamics modeling to represent feedback loops and decision-making in the DDP.
  • Analysis of the impact of early-stage decisions on overall DDP performance.
  • Integration of technology and knowledge-based strategies within the DDP framework.

Main Results:

  • The proposed system dynamics structure can characterize the link between technology and critical management decisions.
  • The model highlights how early-stage decisions and feedback loops affect later development stages.
  • Integrated approaches show potential for reducing early attrition rates and improving lead identification.

Conclusions:

  • System dynamics provides a valuable framework for understanding and improving the complex DDP.
  • Enhanced decision-making through integrated technology and knowledge-based approaches can optimize early-phase drug discovery.
  • Addressing systemic issues in DDP is crucial for reducing time delays and improving R&D efficiency.